IRON Disc Medicine Corp: Net earnings per one share for the last twelve months

Public company logo of Disc Medicine Inc (IRON)

Risks for Disc Medicine, Inc. (IRON) stem from a narrow development pipeline, where failures in blood research threaten a collapse in share prices. Meanwhile, laboratories operate strictly according to protocol, ensuring capacity readiness for synthesis. Growth prospects are driven by the success of bitopertin and DISC-0974, as well as interest from major pharma behemoths. The 12-month YoY change in net income per share on this GURU.Markets chart is -18.00, reflecting the EPS dynamics.

Disc Medicine Inc (IRON): Net earnings per share (EPS TTM) from 02/11/2024 to 11/18/2026

discmedicine.com - analytical breakdowns and key metrics (IRON)

- share price and expert price forecast:
Initial company analysis:IRON (Disc Medicine)
Finished products of Disc Medicine, Inc.

Year-over-year (TTM) EPS growth measures the dynamics of net income per share over twelve months, allowing for an assessment of actual capitalization efficiency and business growth momentum. For Disc Medicine, Inc. (IRON), the EPS YoY TTM shift reflects the extent to which AI-driven drug synthesis automation converts into financial results against the backdrop of clinical trial expenditures.